Table 6.
Background of patients for phase trios in Table 1A
| Variable | Group T1 (262) | Group T1 + group T2 (332) | Group T3 (123) | Group T4 (55) | P value (group T1 versus T4) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of missing data | Mean value (fraction) | Standard deviation | Number of missing data | Mean value (fraction) | Standard deviation | Number of missing data | Mean value (fraction) | Standard variation | Number of missing data | Mean value (fraction) | Standard variation | ||||
| MTX dosage | Phase before A | 0 | 7.27 | 1.13 | 0 | 7.04 | 1.33 | 0 | 7.18 | 1.22 | 0 | 8.00 | |||
| (mg/week) | Phase A | 0 | 10.08 | 1.56 | 0 | 10.23 | 1.81 | 0 | 10.49 | 1.24 | 0 | 8.00 | |||
| Phase after A | 0 | 11.00 | 1.85 | 0 | 10.03 | 2.61 | 0 | 10.49 | 1.24 | 0 | 8.00 | ||||
| DAS28–ESR | Phase before A | 2 | 4.30 | 1.21 | 2 | 4.23 | 1.21 | 2 | 4.16 | 1.25 | 0 | 3.66 | 1.23 | <0.001 | |
| Phase A | 11 | 4.00 | 1.18 | 16 | 3.93 | 1.18 | 8 | 3.67 | 1.20 | 3 | 3.49 | 1.16 | <0.005 | ||
| Phase after A | 15 | 3.74 | 1.13 | 18 | 3.71 | 1.12 | 12 | 3.62 | 1.19 | 2 | 3.41 | 1.24 | |||
| Folic acid | Phase A | 0 | 0.50 | 0 | 0.47 | 0 | 0.47 | 0 | 0.31 | ||||||
| PSL dosage (mg) | Phase A | 0 | 2.14 | 2.79 | 0 | 2.13 | 2.77 | 0 | 2.13 | 2.59 | 0 | 1.98 | 2.81 | ||
| Sex | Male: 0 and female: 1 | 0 | 0.82 | 0 | 0.83 | 0 | 0.83 | 0 | 0.84 | ||||||
| Age at onset | years | 3 | 43.37 | 13.00 | 4 | 43.68 | 13.06 | 0 | 43.15 | 13.05 | 0 | 42.89 | 14.31 | ||
| Age | years | 0 | 53.33 | 12.54 | 0 | 53.81 | 12.47 | 0 | 54.38 | 11.60 | 0 | 53.85 | 12.91 | ||
| Duration of RA | years | 3 | 10.05 | 7.59 | 4 | 10.20 | 7.89 | 0 | 11.23 | 8.00 | 0 | 10.96 | 8.23 | ||
| Height | cm | 6 | 158.41 | 7.46 | 8 | 158.09 | 7.36 | 3 | 158.15 | 7.13 | 0 | 158.45 | 8.00 | ||
| Weight | kg | 8 | 53.41 | 9.62 | 11 | 53.21 | 9.40 | 4 | 53.66 | 9.43 | 0 | 54.98 | 9.66 | ||
| BMI | kg/m2 | 8 | 21.20 | 2.97 | 11 | 21.22 | 2.94 | 4 | 21.39 | 3.27 | 0 | 21.84 | 2.96 | ||
| JHAQ | 0 | 0.85 | 0.66 | 0 | 0.86 | 0.68 | 0 | 0.87 | 0.70 | 0 | 0.79 | 0.72 | |||
| Number of tender joints | 45 joints | 4 | 4.38 | 6.30 | 7 | 4.22 | 6.03 | 2 | 3.99 | 5.70 | 3 | 3.29 | 4.37 | ||
| Number of swollen joints | 45 joints | 4 | 4.22 | 4.50 | 7 | 4.05 | 4.37 | 2 | 4.26 | 4.33 | 3 | 2.83 | 3.25 | <0.01 | |
| Pain–VAS | 100 mm | 2 | 40.40 | 26.24 | 2 | 40.10 | 26.20 | 0 | 40.11 | 26.61 | 0 | 32.11 | 27.61 | ||
| GH | 100 mm | 1 | 39.85 | 23.96 | 1 | 40.01 | 24.15 | 0 | 38.48 | 24.09 | 0 | 32.09 | 24.93 | ||
| Doctor–VAS | 100 mm | 2 | 24.01 | 18.54 | 3 | 23.19 | 18.42 | 0 | 23.27 | 18.50 | 2 | 23.30 | 18.16 | ||
| CRP | mg/dl | 6 | 2.00 | 2.19 | 8 | 1.89 | 2.13 | 2 | 1.88 | 2.12 | 3 | 1.00 | 1.71 | <0.0005 | |
| ESR | mm/h | 7 | 45.51 | 24.02 | 10 | 44.52 | 24.49 | 3 | 43.55 | 24.62 | 4 | 29.30 | 19.22 | <10−6 | |
| RF | U/ml | 7 | 153.79 | 244.83 | 9 | 145.39 | 227.37 | 2 | 129.31 | 178.26 | 4 | 100.69 | 140.50 | ||
| GPT | IU/l | 7 | 22.45 | 19.43 | 9 | 22.16 | 18.27 | 3 | 24.58 | 23.31 | 4 | 28.78 | 21.96 | ||
| GOT | IU/l | 7 | 22.09 | 12.38 | 9 | 21.95 | 11.59 | 3 | 23.53 | 14.75 | 4 | 26.82 | 14.15 | <0.05 | |
| WBC | /mm3 | 7 | 7288.63 | 2334.61 | 10 | 7222.98 | 2,304.07 | 3 | 7,284.17 | 2,167.48 | 5 | 7,144.00 | 1,948.43 | ||
| RF (±) | 7 | 0.84 | 0.37 | 9 | 0.83 | 0.38 | 2 | 0.79 | 0.41 | 4 | 0.82 | 0.39 | |||
| NSAID | Fraction | 0 | 0.85 | 0 | 0.84 | 0 | 0.86 | 0 | 0.84 | ||||||
| Steroid | Fraction | 0 | 0.44 | 0 | 0.44 | 0 | 0.46 | 0 | 0.38 | ||||||
| BUC | Fraction | 0 | 0.18 | 0 | 0.17 | 0 | 0.17 | 0 | 0.16 | ||||||
| SSZ | Fraction | 0 | 0.24 | 0 | 0.25 | 0 | 0.20 | 0 | 0.16 | ||||||
| DPC | Fraction | 0 | 0.03 | 0 | 0.03 | 0 | 0.04 | 0 | 0.04 | ||||||
| GST | Fraction | 0 | 0.08 | 0 | 0.07 | 0 | 0.08 | 0 | 0.02 | ||||||